Drugs / Covid-19 (recombinante) vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05142488 | Nov 2021 → Mar 2022 | COVID-19 | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Unknown | No outcome recorded |
| Phase 4 | NCT05157178 | Jul 2021 → Mar 2022 | COVID-19 | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Covid-19 (recombinante) vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05157178 ↗ |
| Modality | Vaccine | “Covid -19 (recombinante) vaccine” NCT05142488 ↗ |